Bonalive is a smart biomaterials company transforming the future of healthcare. With one of the most evidence-based technologies in the industry, we are creating a smarter future for healthcare. Bonalive is an ISO 13485:2016 certified, Class III medical device company.
Dr. Ollila founded Bonalive Biomaterials Ltd in 2009, through an MBO of the Bonalive® technology from Vivoxid Ltd. Before he became Chairman and CEO, he completed a post-doc and worked in project management at Novartis Pharma in Switzerland. In addition, Dr. Ollila was also the Global Director of Sales and Marketing at Vivoxid Ltd. He holds a PhD in biochemistry and has an international background, having lived in Finland, Spain, Switzerland and the USA.
Mr. Lucchesi holds a Bachelor of Science in Engineering and joined Bonalive in 2009, after holding several positions as a Research Scientist, Business Development Manager and R&D Manager in different organizations. He has thorough knowledge of the Bonalive technologies and brings his vast experience to the company. Mr. Lucchesi coordinates Bonalive’s scientific projects and oversees their technological development.
Mrs. Rantala joined Bonalive in 2009 after having held several positions in R&D, quality control and project management. A process-oriented thinker, Rantala believes in a lean working philosophy and mentor-based leadership. She holds a degree in laboratory sciences and is a member of the Finnish Production Management Association.
Mrs. Lumiainen joined Bonalive in 2009, after having worked for Vivoxid Ltd since 2002. She has vast experience in marketing and product management, brand design and HR tasks. She holds a Master of Science in Social Sciences and Bachelor of Science in Business Administration.
Mrs. Lindgren joined Bonalive in 2009, after holding several positions in quality assurance and management since 2001. Mrs. Lindgren brings experience in ensuring Bonalive’s compliance with regulatory requirements and is a qualified lead auditor. Mrs. Lindgren holds a Master of Science degree in Chemistry.
Dr. Airola holds a PhD in Chemistry and joined Bonalive in 2016, bringing with him 20 years of experience in IPR, quality and supplier management. He is familiar with both industrial and start-up environments and assumed the role of Director of Quality at Bonalive in 2018.
Ms. Valtanen joined Bonalive in 2011 adding her significant experience in project management, corporate financing and accounting to the company. Ms. Valtanen holds a Master of Science in Economics and Business Administration.
(Currently on maternity leave)
Board of Directors
Dr. Ollila has served as Member of the Board of Directors since 2009 and assumed the role of Chairman of the Board in 2018. He founded Bonalive Biomaterials Ltd in 2009 through a management buy-out of the Bonalive® technology from Vivoxid Ltd. Before his current position as a Chairman and CEO of Bonalive, Dr. Ollila completed a post-doctoral thesis and worked at Novartis Pharma in Switzerland for several years. He was also the Global Director of Sales and Marketing at Vivoxid Ltd. Ollila holds a doctorate in biochemistry from Åbo Akademi University.
Assoc. Prof. Frantzén has been a Member of the Board of Directors since 2013. As a consultant neurosurgeon and Associate Professor at the Turku University Hospital, Frantzén has extensive experience in the clinical use of bioactive glass in spine surgery. Frantzén holds a PhD in Neurosurgery from the University of Turku.
Mr. Muñoz has been a Member of the Board of Directors since 2017. He has extensive international experience from China, India and Colombia. Currently he serves as a New Business Manager (NBO) and Business Development Director at Avalon Pharmaceuticals.
Mr. Lucchesi joined the company in 2009 from Vivoxid Ltd., where he worked as Buseiness Development Manager. He has been a deputy member of the Board of Directors since 2015. Currently he is Chief Technology Officer at Bonalive. Mr. Lucchesi is well versed in R&D, manufacturing and scientific research and holds a Bachelor of Science in Engineering.
Chronic osteomyelitis and infected non-union treatmentMay 24, 2018 09:48
A new publication has been published on the use of Bonalive bioactive glass in Infected Non-Unions and Chronic Osteomyelitis treatment. Infection with a single pathogen was demonstrated in 50% of...
Bonalive is a proud Platinum Sponsor of ESTROT 2018May 24, 2018 09:35
We look forward to seeing you at ESTROT 2018.
Cost-effectiveness of Bonalive® granulesMarch 28, 2018 09:51
A recent congress paper at the ORS 2018 Annual Meeting compares the cost-effectiveness of a one-stage treatment of chronic osteomyelitis using Bonalive® granules with a two-stage treatment using gentamicin loaded...
Bonalive is EBJIS 2018 Gold SponsorMarch 28, 2018 09:50
We are thrilled to welcome you to the 37th annual meeting of the EBJIS hosted in the capital of Finland, home country of BonAlive. BonAlive will be the Gold Sponsor...
Bonalive® in mastoidal infections surgeryDecember 19, 2017 10:01
A new doctoral thesis on BonAlive® bioactive glass S53P4 in chronic middle ear treatment and mastoidal infections surgery has been published. According to the study, bioactive glass (BG S53P4) is...
World Antibiotic Awareness WeekDecember 13, 2017 10:04
BonAlive Biomaterials participates in the World Health Organization World Antibiotic Awareness Week. Learn how to handle antibiotics with care.
New clinical articles of Bonalive® granulesOctober 17, 2017 10:05
In our continuous effort to improve science and to supply our worldwide customer network with new clinical data, we have the pleasure to present three new clinical articles where BonAlive®...
Bonalive Biomaterials Ltd
Tel. +358 401 77 44 00
Biolinja 12, 20750 Turku, Finland
ISO 13485:2016 certified
Bonalive® granules, Bonalive® putty and Bonalive® putty MIS are CE marked products.